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ABSTRACT
A patient with extensive cutaneous chronic graft-versus-host disease (cGVHD) affecting 100% of the body sur-
face, with painful ulcerations that involved 20% of it, was treated unsuccesfully during 9 months with steroids,
cyclosporine-A (CSa), sirolimus, tacrolimus, mychophenolate mofetil (MMF), infliximab, and rituximab.
Twenty-one months after the allograft the patient was started on alemtuzumab, 10 mg/day subcutaneously,
for 6 consecutive days every 4 weeks. Seven months after starting the treatment, 100% of the ulcers had
disappeared, as had the pain. To our knowledge, there are no reports of the use of alemtuzumab in the treatment
of extensive, ulcerated, refractory cutaneous cGVHD. The data presented here suggest that this agent may be
useful in some patients with refractory forms of cGVHD.
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Chronic graft-versus-host disease (cGVHD) is
a common complication following allogeneic hemato-
poietic cell transplantation (HCT); it is the leading
cause of nonrelapse mortality (NRM) in transplant
survivors and has a significant impact upon their
functional status and quality of life. Despite significant
advances in the field of HCT in recent years, there has
been little change in the incidence, morbidity, and
mortality of cGVHD [1]. The main clinical targets
of GVHD are the skin, liver, gastrointestinal tract,
and possibly the lungs. The standard initial therapy
for GVHD includes the use of high-dose steroids,
which result in an unsatisfactory complete response
rate of about 40% and the need to develop more
effective therapies [2]. Etanercept, mycophenolate
mofetil (MMF), denileukin diftitox, pentostatin, ritux-
imab, daclizumab, sirolimus (rapamycin), basiliximab,
thalidomide, extracorporeal photopheresis, and other
approaches have been tried, with variable results [2].
Skin is the most frequently affected organ in cGVHD
and manifestations are highly variable [3-4].
Alemtuzumab (Campath 1H) is an unconjugated,
humanized IgG1 kappa monoclonal antibody which
targets the CD52 antigen on T and B lymphocytes,as well as on monocytes, macrophages, eosinophils,
and dendritic cells [5]. This antibody has been used
in the conditioning regimens employed for allogeneic
HCT to remove donor T cells so as to preventGVHD,
however, only a few patients have received this anti-
body for the treatment of established GVHD, and
only anecdotal information is available in this setting
[6-10]. Alemtuzumab has also been used to treat
autoimmune diseases [11].
We describe the case of a female patient with a se-
vere, ulcerated refractory form of cutaneous cGVHD
who had received, unsuccessfully, several treatments.
She finally cleared the cutaneous ulcers and the pain
with the use of subcutaneous alemtuzumab.
CASE REPORT
A 19-year-old woman was diagnosed with M2
acute myelogenous leukemia (AML) in January 2003.
Her blast cells expressed CD7, CD13, CD33, CD34,
and CD45. After achieving a complete remission
with conventional chemotherapy, a relapse ensued in
October 2003. She was then induced to a second re-
mission and afterwards, allografted from her HLA
identical male sibling in December 2003, using a con-
ventional conditioning regimen. Cytomegalovirus7
8 G. J. Ruiz-Argu¨elles et al.(CMV) serology (IgG) was positive both in the donor
and the patient. Without having developed acute
GVHD (aGVHD), extensive cutaneous GVHD en-
sued 1 year after the allograft, affecting 100% of the
body surface. The skin lesions were initially lichenoid,
but some progressed to overt painful ulcerations de-
spite treatment. Treatment consisted of oral steroids
(prednisone) for 7 months; cyclosporine-A (CSa) for
7 months; sirolimus, tacrolimus, and for 1 month
each; one dose of infliximab and two doses of rituxi-
mab. All these drugs were administered unsuccessfully
to the patient during a 9-month period, and noGVHD
involvement of other organs ensued.
The ulcers evolved until they comprised approxi-
mately 20% of the body surface area (BSA) according
to Greinix et al [12]. At this point, a skin biopsy from
the patient’s right thigh showed a thinned atrophic
epidermis with loss of rete ridges and some dyskera-
totic cells, vacuolar alteration of the interface with
detachment of the epidermis, and a superficial perivas-
cular lymphocytic inflammatory infiltrate with plasma
cells and some eosinophils with a hint of lichenoid pat-
tern, as well as pigment incontinence. Some thickening
of collagen bundles were seen in deeper reticular der-
mis. No appendages were found (Figure 1). After a 1-
month washout period of all the drugs, and 21 months
after the allograft, with an extensive, painful, severe ul-
cerative variant of cutaneous cGVHD (Figure 2), the
patient, with a Karnofsky score of 40% and after giving
her written informed consent, was started on alemtu-
zumab, 10 mg/day subcutaneously, for 6 consecutive
days every 4 weeks. No other immunosuppressive
drugs were delivered. Cotrimoxasole was given pro-
phylactically and CMV antigen was assesed every 2
weeks. Three weeks after starting alemtuzumab, the
cutaneous lesions began to scar. Twenty percent of
the skin surface was ulcerated at the beginning of the
treatment and 0% of the skin surface was ulcerated 7
months later (Figure 2); lichenoid plaques with xerosis,
skin thickening, and limited motion became apparent.
In addition, the pain disappeared completely when theulcers healed. At this point, alemtuzumabwas switched
to 10 mg/week subcutaneously. CMV antigenemia has
remained persistently negative, and the complete
blood cell counts were normal. The patient is currently
a full chimera. She is now able to walk by herself, with
a Karnofsky score of 80%. She received a total of 460
mg of alemtuzumab.
DISCUSSION
cGVHD complicates allogeneic SCT in 6% to
80% of cases, according to variables such as recipient
age, donor age, donor type, stem cell source, graft
manipulation, and the use of donor lymphocyte
infusions [1]. Skin is the most frequently affected
organ, and severe sclerotic features characterized by
thickened tight and fragile skin are often associated
with poor wound healing, inadequate lymphatic
drainage, and skin ulcers from minor trauma [12]. In
cutaneous cGVHD, the combination of corticoste-
roids and cyclosporine is used, whereas other
Figure 1. Skin biopsy obtained before treatment with alemtuzumab.
Thinned and detached epidermis is apparent, with a hint of lichenoid
arrangement of the lymphocytic infiltrate in the upper dermis.Figure 2. A, Skin changes in the right lower limb of the patient prior to the treatment with alemtuzumab; extensive ulcer-
ation is obvious. B, The same region 6 months after the treatment.
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whether lichenoid or sclerodermatous lesions are
present [13]. High response rates to phototherapy
have been found in lichenoid disease, whereas
sclerodermatous disease responds better to etretinate
or extracorporeal photochemotherapy. Localized
cutaneous cGVHD may be treated with topical corti-
costeroids alone, but experience with the treatment of
extensive, ulcerated, refractory cutaneous cGVHD is
limited.
Intravenous administration of alemtuzumab has
been approved in the United States and in Europe
for the treatment of patients with B cell chronic
lymphocytic leukemia. Recent reports suggest that
alemtuzumab can also be delivered subcutaneously
achieving blood levels equivalent to those when given
intravenously [14,15]. As the incidence of the infu-
sion-related events reported using the i.v. route is as
high as 90% [16], we administered the drug subcutane-
ously to minimize adverse events [17]; we also used this
study to test the 10mg/day dose. There are few reports
about the usefulness of alemtuzumab in the treatment
of GVHD [7-10, 16], but most of these reports have
been made regarding individuals with the aGVHD.
To our knowledge, there are no reports of the use
of alemtuzumab in the treatment of extensive cutane-
ous GVHD; additional studies are needed to support
this observation.
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